A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis

Clinical trial NCT03619902 · COMPLETED

Trial details

NCT number: NCT03619902
Sponsor: Vanda Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Generalized Pustular Psoriasis

Start date: 2019-01-30
Primary completion: 2021-01-20
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.